Abstract
The development of a new antileprotic agent poses particular problems in view of the fact that the etilogic agent of human leprosy, Mycobacterium, leprae, cannot be cultured in bacteriologic media. However, a correlation has been observed between minimum inhibitory concentrations (MIC) for Mycobacterium species 607, determined in vitro, and dietary MIC's for M. leprae growing in the mouse footpad 1,2 Clinical therapeutic practice in the treatment of leprosy is largely dependent on the use of 4,4′-diaminodiphenyl sulfone (DDS)3 or hydrolyzable derivatives.4 In an effort to establish the structure-activity requirements of diaryl sulfones relative to our mycobacterial model system we have prepared a series of DDS analogs and evaluated them as growth inhibitors of M. sp. 607.
Original language | English (US) |
---|---|
Pages (from-to) | 142-144 |
Number of pages | 3 |
Journal | Journal of medicinal chemistry |
Volume | 17 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 1974 |
Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery